Abstract

Amyloid beta peptide (Aβ) is implicated in the pathogenesis of Alzheimers disease (AD), particularly as oligomers or polymers that are correlated with Ab cellular toxicity. Inhibition of the formation of toxic forms of Aβ has therefore emerged as one approach to the treatment of AD. This article reviews efforts to adapt the structure of Aβ to the design and testing of peptide-based inhibitors of Aβ polymerization of interest as potential AD therapeutics.

Keywords: Peptide Inhibitors, Beta Amyloid Aggregation, Amyloid beta peptide